Dublin, Nov. 23, 2018 (GLOBE NEWSWIRE) -- The "Cold Chain Logistics Market for Healthcare: Focus on Cell Therapies, Vaccines, and Human Organs, 2018-2030" report has been added to ResearchAndMarkets.com's offering.

The Cold Chain Logistics Market for Healthcare: Focus on Cell Therapies, Vaccines, and Human Organs, 2018-2030' report features an extensive study of the current landscape and future outlook of the growing cold chain logistics services market. The study features an in-depth analysis, highlighting the capabilities of the various service providers engaged in this domain.

Over the years, the growing demand for such products has necessitated the need for well-defined infrastructure and protocols to support cold chain dependent logistics operations. Further, stakeholders in this segment of the industry have designed and established a variety of innovative solutions to serve the evolving demands of the healthcare sector. Moreover, connected cold chain solutions have been observed to offer a variety of advantages over conventional methodologies, such as automation of most of the steps and elimination of human handling errors that are associated with human intervention.

In addition, the industry has witnessed several facility/capability expansions and acquisitions owing to an increasing demand for cold chain logistics services, which is indicative of the growing interest of stakeholders in this particular type of supply chain. Given the recent technological breakthroughs and advances, and the steadily rising demand for biopharmaceuticals, the reliance on cold chain is expected to increase substantially, causing logistics service providers to contemplate, devise and implement flexible business strategies and operational models to cope up with the future needs.

One of the key objectives of the report was to estimate the existing market size and potential growth opportunities for cold chain logistics over the coming decade. Based on several parameters, we have provided an informed estimate of the likely evolution of this market in the short to mid-term and long-term, for the period 2018-2030.

Key Topics Covered:

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Chapter Overview
3.2. Concept of Cold Chain Logistics
3.2.1. Comparison of Conventional Supply Chain and Cold Chain
3.2.2. Historical Evolution of the Cold Chain Logistics Industry
3.3. Cold Chain Logistics in Healthcare
3.4. Types of Healthcare Products Requiring Cold Chain Logistics
3.5. Types of Container used in Cold Chain Logistics
3.5.1. Active Cold Chain Containers
3.5.2. Passive Cold Chain Containers
3.5.3. Insulated Cold Chain Containers
3.6. Modes of Transportation
3.6.1. Road Transportation
3.6.2. Air Transportation
3.6.3. Ocean / Marine Transportation
3.6.4. Rail Transportation
3.6.5. Intermodal and Multimodal Transportation
3.6.6. Comparison of Modes of Transportation
3.7. Advantages and Limitations of Cold Chain Logistics in Healthcare
3.8. Concluding Remarks

4. Cold Chain Logistics For Cell Therapies, Vaccines And Human Organs
4.1. Chapter Overview
4.2. Cold Chain Management for Cell Therapies
4.2.1. An Introduction to Cell Therapies
4.2.2. Classification of Cell Therapies
4.2.3. An Overview of Cell Therapy Logistics
4.2.3.1. Cold Chain Logistics for Autologous Cell Therapies
4.2.3.2. Cold Chain Logistics for Allogeneic Cell Therapies
4.2.3.3. Comparison of Cold Chain Logistics for Autologous and Allogenic Cell Therapies
4.2.4. Cold Storage of Cell Therapies
4.2.5. Challenges Related to Cell Therapy Logistics
4.2.5.1. Process Standardization
4.2.5.2. Packaging and Shipping Qualifications
4.2.5.3. Validation of Storage Containers
4.2.5.4. Logistical Process Qualification
4.2.5.5. Chain-of-Custody Documentation
4.2.6. Strategies to Overcome Existing Challenges in Cell Therapy Logistics
4.2.7. Case-in-Point: Cell Orchestration Platforms for Management of Cell Therapy Logistics
4.3. Cold Chain Management for Vaccines
4.3.1. An Introduction to Vaccines
4.3.2. Classification of Vaccines
4.3.3. An Overview of Vaccine Logistics
4.3.4. Cold Storage of Vaccines
4.3.5. Challenges Related to Vaccine Logistics
4.3.5.1. Heat Sensitivity
4.3.5.2. Cross-Border Shipments
4.3.5.3. Choice of Suitable Containers
4.4. Cold Chain Management for Human Organs
4.4.1. An Introduction to Human Organ Transplantation
4.4.2. An Overview of Human Organ Logistics
4.4.3. Storage / Preservation of Human Organs
4.4.4. Challenges Related to Human Organ Logistics
4.4.4.1. Organ Matching
4.4.4.2. Organ Viability
4.4.4.3. Organ Packaging, Labelling and Transportation
4.4.5. Case-in-Point: Beating Heart-in-a-Box
4.5. Logistical Complexity Analysis for Different Products

5. Market Landscape
5.1. Chapter Overview
5.2. Cold Chain Logistics Service Providers: List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Location of Headquarters
5.2.3. Analysis by Size of Company
5.2.4. Analysis by Type of Products
5.2.5. Analysis by Type of Cold Chain Logistics Service(s)
5.2.6. Analysis by Mode of Transportation
5.2.7. Analysis by Holding Temperature Range
5.2.8. Analysis by Type of Containers
5.2.9. Analysis by Type of End-Users
5.2.10. Analysis by Geographical Activity
5.2.11. Analysis by Location of Cold Chain Facility
5.3. List of Cold Chain Logistics Service Providers for Other Healthcare Products
5.4. List of Equipment / Technologies for Cold Chain Logistics

6. Company Competitiveness Analysis
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Parameters
6.4. Cold Chain Logistics Service Providers: Competitive Landscape
6.4.1. Small-sized Companies
6.4.2. Mid-sized Companies
6.4.3. Large Companies

7. Company Profiles
7.1. Chapter Overview
7.2. Cryoport
7.3. Lynden International Logistics
7.4. PAREXEL
7.5. DHL Express
7.6. United Parcel Service
7.7. GAC
7.8. Yusen Logistics

8. Recent Partnerships And Expansions
8.1. Chapter Overview
8.2. Partnership Models
8.3. Cold Chain Logistics in Healthcare: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Product
8.3.4. Analysis by Type of Cold Chain Logistics Service
8.3.5. Analysis by Type of Cold Chain Logistics Service and Type of Product
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Regional Analysis
8.3.7.1. Intercontinental and Intracontinental Agreements
8.4. Cold Chain Logistics in Healthcare: Mergers and Acquisitions
8.4.1. Year-Wise Trend
8.4.2. Most Active Acquirers: Analysis by Number of Acquisitions
8.5. Cold Chain Logistics in Healthcare: Recent Expansions

9. Regulatory Recommendations And Guidelines
9.1. Chapter Overview
9.2. Regulatory Guidelines Issued by International Authorities
9.2.1. World Health Organization (WHO)
9.2.2. International Air Transport Association (IATA)
9.2.3. International Committee on Harmonisation (ICH)
9.2.4. International Safe Transit Association (ISTA)
9.2.5. Parenteral Drug Association (PDA)
9.3. Regulatory Guidelines for Cold Chain Management in the US
9.3.1. United States Food and Drug Administration (USFDA)
9.3.2. United States Pharmacopeia (USP)
9.4. Regulatory Guidelines for Cold Chain Management in Canada
9.4.1. Health Canada
9.5. Regulatory Guidelines for Cold Chain Management in Europe
9.5.1. European Medicine Agency (EMA)
9.6. Recommendations for Different Steps of Cold Chain Logistics
9.7. Comparative Analysis of Regulatory Authorities

10. Case Study: Cold Chain Requirements For Approved Drugs
10.1. Chapter Overview
10.2. List of USFDA Approved Drugs
10.2.1. Analysis by Year of Approval
10.2.2. Analysis by Type of Molecule
10.2.3. Analysis by Type of Biologic
10.2.4. Analysis by Holding Temperature Range
10.2.5. Analysis by Dosage Form and Holding Temperature Range
10.2.6. Analysis by Route of Administration and Holding Temperature Range
10.2.7. Most Active Players: Analysis by Number of Approved Drugs Requiring Cold Chain

11. Demand Analysis For Cell Therapies
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Cell Therapies, Global Clinical Demand: Analysis by Number of Trials
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Type of Cell Therapy
11.3.3. Analysis by Trial Phase
11.3.4. Analysis by Type of Cell Therapy and Trial Phase
11.3.5. Analysis by Therapeutic Indications
11.3.6. Geographical Analysis by Number of Clinical Trials
11.3.7. Geographical Analysis by Type of Cell Therapy and Trial Phase
11.3.8. Analysis by Type of Sponsors / Collaborators
11.3.9. Most Active Players
11.4. Cell Therapies, Global Clinical Demand: Analysis by Enrolled Patient Population
11.4.1. Analysis by Type of Cell Therapy
11.4.2. Geographical Analysis by Enrolled Patient Population
11.4.3. Geographical Analysis by Type of Cell Therapy and Trial Phase
11.5. Cell Therapies, Global Commercial Demand: Analysis by Expected Number of Product Approvals
11.6. Cell Therapies, Global Commercial Demand: Analysis by Target Patient Population
11.7. Concluding Remarks

12. Demand Analysis For Vaccines
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Vaccines, Global Clinical Demand: Analysis by Number of Trials
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis by Holding Temperature Range
12.3.3. Analysis by Trial Phase
12.3.4. Analysis by Trial Status
12.3.5. Geographical Analysis by Number of Clinical Trials
12.3.6. Geographical Analysis by Trial Status and Trial Phase
12.3.7. Analysis by Type of Sponsors / Collaborators
12.3.8. Most Active Players
12.4. Vaccines, Global Clinical Demand: Analysis by Enrolled Patient Population
12.4.1. Geographical Analysis by Enrolled Patient Population
12.4.2. Geographical Analysis of Enrolled Patient Population by Trial Phase and Holding Temperature Range
12.5. Vaccines, Global Commercial Demand: Analysis by Type of Vaccine
12.5.1. Demand for Mandatory Vaccines: Global Scenario
12.5.2. Demand for Mandatory Vaccines: Distribution by Geography
12.5.2.1. Present Demand (2018 Scenario)
12.5.2.2. Estimated Demand in the Short Term (2025 Scenario)
12.5.2.3. Estimated Demand in the Long Term (2030 Scenario)
12.5.3. Demand for Optional Vaccines: Global Scenario
12.5.4. Demand for Optional Vaccines: Distribution by Geography
12.5.4.1. Present Demand (2018 Scenario)
12.5.4.2. Estimated Demand in the Short Term (2025 Scenario)
12.5.4.3. Estimated Demand in the Long Term (2030 Scenario)
12.6. Vaccines, Global Commercial Demand: Analysis by Number of Patients
12.7. Vaccines, Global Commercial Demand: Analysis by Number of Doses
12.8. Concluding Remarks

13. Demand Analysis For Human Organs
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Human Organs, Global Demand: Distribution by Geography
13.3.1. Present Demand (2018 Scenario)
13.3.2. Estimated Demand in the Short Term (2025 Scenario)
13.3.3. Estimated Demand in the Long Term (2030 Scenario)
13.3. Human Organs, Global Demand: Analysis by Type of Organ
13.3.1. Kidney
13.3.2. Liver
13.3.3. Heart
13.3.4. Lung
13.3.5. Pancreas and Intestine
13.4. Human Organs, Overall Global Demand
13.5. Concluding Remarks

14. Market Forecast

15. SWOT Analysis
15.1. Chapter Overview
15.2. Strengths
15.3. Weakness
15.4. Opportunities
15.5. Threats
15.6. Comparison of SWOT Factors

16. Upcoming Trends And Future Growth Opportunities
16.1. Chapter Overview
16.2. Connected Cold Chain: Key Tools And Technologies
16.2.1. Artificial Intelligence
16.2.2. Augmented Reality
16.2.3. Automation and Robotics
16.2.4. Big Data Analytics
16.2.5. Blockchain Technology
16.2.6. Cloud Computing
16.2.7. Internet of Things
16.2.8. Radio Frequency Identification (RFID) Tags
16.3. Connected Cold Chain: Future Growth Opportunities
16.4. Real-Time Monitoring: An Application of Connected Cold Chain Solutions
16.4.1. Methods for Integration of Real-Time Monitoring in Cold Chain Logistics
16.4.1.1. RFID Based Real-Time Monitoring
16.4.1.2. Blockchain and IoT Based Real-Time Monitoring
16.4.2. Growth Opportunities for Real-Time Monitoring in Connected Cold Chain
16.4.3. Cost Benefits of Real-Time Monitoring in Cold Chain Logistics

17. Executive Insights
17.1. Chapter Overview
17.2. AirBridgeCargo Airlines
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Elena Boykova, Marketing Communications Manager
17.3. Cell and Gene Therapy Catapult
17.3.1. Company Snapshot
17.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer
17.4. UNICEF
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Michelle Arnot-Kruger, Health Specialist, Cold Chain Logistics
17.5. Tabuk Pharmaceuticals
17.5.1. Company Snapshot
17.5.2. Interview Transcript: Shehdeh Abusnineh, Supply Chain Manager

18. Appendix 1: Tabulated Data

19. Appendix 2: List Of Companies And Organizations

For more information about this report visit https://www.researchandmarkets.com/research/fl866r/global_healthcare?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Logistics, Industrial Refrigeration